Hot Sale Peptides Tirze Retatrutide Sema Oxytocin Mt2 Epithalon Ll37 P21 VIP Ghk Cu Semax Good Price Raw Powder
9 Inquiries
2920938-90-3
Pharmaceutical Grade
99%
Shenzhen
CQ
bag
2026-08-31
Tirzepatide,Retatrutide,Semaglutide,Cagrilintide,NAD+,copper peptide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionBasic Info
-
Product Name:
N-Acetyl Semax
Other Name:Polypeptide Impurity 29 (N-Acetyl Semax Amidate);N-Acetyl Semax Amidat;AC-SEMAX
CAS No.:2920938-90-3
Molecular Formula:C39H54N10O10S
InChIKeys:QQOAKFVAEDCKGY-HPMAGDRPSA-N
Molecular Weight:854.97
Categories:
Characteristics-
Density:
1.364±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)
Boiling Point:1422.9±65.0 °C(predicted)
PKA:4.43±0.10(predicted)
Research-
Class:
Triple agonist — GCGR, GIPR, GLP-1R
Status:Investigational (Phase 3)
Mechanism:Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.
EC50 (Human GCGR):5.79 nM
EC50 (Mouse GIPR):0.191 nM
EC50 (Mouse GLP1R):0.794 nM
EC50 (Mouse GCGR):2.32 nM
EC50 (Human GLP1R):0.775 nM
EC50 (Human GIPR):0.0643 nM
Source:Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI
Clinical Development:
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,Semaglutide,Cagrilintide,NAD+,copper peptide
-
Location:
room 102, No. 60-20, Gongnong Street, Xiangya Road Subdistrict, Kaifu District, Changsha City, Hunan Province, China
-
Payment Terms:
TT against copy of documents,D/P,L/C,TT against B/L draft before shipment
-
Average lead Time:
2
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2023
-
-
Inquiry History9 Inquiries
Country Product Purchase Quantity Date Posted
United States
N-Acetyl Semax Amidate
1 G Dec 31, 2025
United States
N-Acetyl Semax Amidate
5 G Aug 5, 2026
North Macedonia
N-Acetyl Semax Amidate
1 KG Jul 17, 2026
United Arab Emirates
N-Acetyl Semax Amidate
100 MG Mar 10, 2026
India
N-Acetyl Semax Amidate
1000 MG Dec 8, 2025
India
NA Semax amidate
1 KG Dec 8, 2025
United States
N-Acetyl Semax Amidate
1 G Aug 8, 2026
Serbia
n-acetyl semax
100 MG Apr 1, 2026
United States
N-acetyl semax amidate
10 PCS Sep 15, 2025 Post an enquiry for this product